Subnavigation
- Project 1 - CaSR-mediated signalling in colonocytes
- Project 2 - Evaluation of CaSR - based therapeutics in prevention of tumourigenesis and metastatic potential in colorectal cancer
- Project 3 - Role of the CaSR in inflammatory lung diseases
- Project 4 - Evaluation of CaSR-targeted drugs for the treatment of neuroblastoma
- Project 5 - Delineation of CaSR signalling in primary cells and cell lines with native receptor expression
- Project 6 - Role of the calcium-sensing receptor (CaSR) in glucose homeostasis
- Project 7 - Cell-specific CaSR signaling
- Project 8 - Targeting CaSR in human skeletal muscle cells to delay sarcopenia development
- Project 9 - Evaluation of CaSR-targeted drugs for the treatment of diabetes mellitus
- Project 10 - Role of the CaSR in early bone metastasis of breast cancer cells and evaluation of CaSR - based therapeutics in prevention or delay of metastasis formation
- Project 11 - Ligand-biased G-protein activation by CaSR
- Project 12 - The role of CaSR in AD pathomechanisms
- Project 13 - In silico analysis of CaSR-ligand interaction
- Project 14 -Generation, validation and application of algorithms for tissue segmentation used in advanced tissue cytometry
Inhaltsbereich
Project 9 - Evaluation of CaSR-targeted drugs for the treatment of diabetes mellitus
Host Institution: The Chancellor, Masters and Scholars of the University of Oxford
» Info
Hypothesis: Selective CaSR antagonists improve insulin secretion and glucose tolerance in diabetes models.
Objectives: 1) Characterise effects of CaSR antagonists (calcilytics) on islet function and insulin secretion; 2) Evaluate glucose-lowering effect of calcilytic drugs in mouse models with impaired insulin secretory responses.
Quick Links
Featured
